Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - epirubicin (epirubicin hydrochloride) - solution for injection/infusion - 2mg/ml

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

clinigen healthcare ltd - dexrazoxane - powder and solvent for solution for infusion - 500mg

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - epirubicin hydrochloride - solution for inj/inf - 2 micromol - anthracyclines and related substances

Kanada - Ingliż - Health Canada

pfizer canada ulc - dexrazoxane - powder for solution - 250mg - dexrazoxane 250mg - miscellaneous therapeutic agents

Kanada - Ingliż - Health Canada

pfizer canada ulc - dexrazoxane - powder for solution - 500mg - dexrazoxane 500mg - miscellaneous therapeutic agents

Stati Uniti - Ingliż - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - adriamycin (doxorubicin hcl) for injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] severe hepatic impairment (defined as child pugh class c or serum bilirubin level greater than 5 mg/dl) [see warnings and precautions

Stati Uniti - Ingliż - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hcl for injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma - metastatic transitional cell bladder carcinoma - metastatic thyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] 

Malta - Ingliż - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 50 mg - antineoplastic agents

Malta - Ingliż - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - epirubicin hydrochloride - solution for infusion or injection - epirubicin hydrochloride 200 mg - antineoplastic agents

Malta - Ingliż - Medicines Authority

accord healthcare limited - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 5 mg/m3 - antineoplastic agents